ArticleJournal of endocrinological investigation2020
Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center.
Article in Journal of endocrinological investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Effects of 6-month treatment with the GLP-1 receptor agonist liraglutide on 24-hour energy metabolism and body composition in adults with obesity.Journal of endocrinological investigation · 2025Article
- Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.European journal of medical research · 2025Observational
- Incretin-based therapies for the treatment of obesity-related diseases.npj metabolic health and disease · 2024Review
- Correlation between type 2 diabetes mellitus remission and intrapancreatic fat deposition.World journal of clinical cases · 2024Article
- Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity.Cureus · 2023Article
- Five-year Weight Loss Maintenance With Obesity Pharmacotherapy.The Journal of clinical endocrinology and metabolism · 2023Article
- Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.Obesity (Silver Spring, Md.) · 2023Observational
- Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review.Therapeutic advances in chronic disease · 2022Review
- Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland.Obesity facts · 2021 · on this mapObservational
- Liraglutide is an effective drug for the treatment of obesity also in real life.Journal of endocrinological investigation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
purposeSeveral randomized controlled clinical trials (RCCTs) have shown that the use of Liraglutide (L) in addition to diet and exercise in patients with obesity or overweight (OO), compared to dietary behavioral changes alone, leads to a significantly greater weight loss. This retrospective study aimed at evaluating the effectiveness of L therapy in a real-life setting.
methods93 consecutive non-diabetic OO, referring to a single Obesity Center, started L therapy from October 2016 to December 2018: 21/93 OO discontinued the treatment within 90 days for various reasons. 72/93 OO (55 females, 17 males), mean ± SD age 49 ± 12.5 years (18-78) and mean body mass index 39.1 ± 5.8 (28.3-55.3) were included for further analysis. 60/72 OO reached the final dose of 3.0 mg/day.
resultsMean weight loss was 7.1% in the OO who reached the dose of 3.0 mg; 68.3%, 20.0% and 10.0% of OO lost ≥ 5%, 10% and 15% of body weight, respectively. A linear correlation between early and final weight loss was found. Moreover, we observed a significant reduction of mean systolic and diastolic blood pressure and a significant increase of mean heart rate. The overall incidence of side effects was 18.3% (17/93).
conclusionL treatment of OO in a real life setting yielded results comparable to those reported by the major RCCTs. Combining the results of RCCTs with the observations from real life may increase their power and overcome their respective limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.